Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.43 |
| ▸ | NPY1R | P25929 | 11/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.43 |
| ▸ | NPY2R | P49146 | 7/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308386 | 0.88 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL30643187 | 0.88 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| Leupeptin SCHEMBL583830 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL11021602 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL4669504 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL13933715 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1818349 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13724544 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL11596919 | 0.86 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Hydrochloric Acid SCHEMBL11137940 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968516-B2 | Taurine, cysteic acid residue and residue of a protease or calpain inhibitor; directly, indirectly bonded to each other;leucyl argininal residues in form of aldehyde; effective to inhibit calpains; acetal prodrug residues can be converted to the aldehyde form before, during, or after administration | ProTor Pharma Corporation (US) | 2011-06-28 | — | — | US | disclosed |